1 Department of Paediatrics and Child Health, Equator University of Science and Technology, Masaka City, Uganda.
2 Department of Paediatrics, Masaka Regional Referral Hospital, Masaka City, Uganda.
3 Medical Officer, Case Hospital Entebbe Kitooro, Uganda.
World Journal of Advanced Research and Reviews, 2025, 26(03), 2680-2683
Article DOI: 10.30574/wjarr.2025.26.3.1965
Received on 09April 2025; revised on 25 June 2025; accepted on 28 June 2025
Biologic therapies play a significant role in reducing exacerbations, hospitalizations and the need for maintenance systemic steroids, while also improving the quality of life in patients with severe asthma. The evidence for their clinical efficacy comes from randomised controlled trials (RCTs), extension studies, metanalyses and real-world data.Biologics offer significant benefits for managing severe asthma, particularly for individuals with type 2 inflammation, by reducing exacerbations, improving lung function, and enhancing quality of life, according to the ERS. These medications target specific inflammatory pathways involved in asthma, leading to improved control and reduced reliance on oral corticosteroids.
Asthma; Children; Biologics; Uganda
Preview Article PDF
Andrew Kiboneka, Babirye Nicolette and Ronnie Mwesigwa. Biologics for Moderate to Severe Asthma in Children From the department of Paediatrics at Masaka Regional Referral Hospital, UGANDA: A case series. World Journal of Advanced Research and Reviews, 2025, 26(3), 2680-2683. Article DOI: https://doi.org/10.30574/wjarr.2025.26.3.1965